TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate
Brief Summary: The purpose of this study is to determine whether childhood atopic disease decrease or not after allowing allergic mothers intake of probiotic (Lactobacillus GG) in second trimester, followed by infant intake for 6 months after birth.


Options:
A: Arm Label: VSL#3 probiotic preparation; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: VSL#3 probiotic preparation | Arm Label: Placebo VSL#3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo VSL#3 | Intervention Type: DIETARY_SUPPLEMENT; Name: VSL#3 probiotic preparation; Assigned to Arm(s): VSL#3 probiotic preparation | Intervention Type: OTHER; Name: Placebo VSL#3; Assigned to Arm(s): Placebo VSL#3
B: Arm Label: Undernourished Pregnant Women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nourished Pregnant Women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Overweight/obese Pregnant women; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Undernourished + Yogurt Pregnant Women; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Moringa and Lactobacillus rhamnosus GR-1 | Arm Label: Nourished + Yogurt Pregnant Women; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Moringa and Lactobacillus rhamnosus GR-1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Moringa and Lactobacillus rhamnosus GR-1; Assigned to Arm(s): Nourished + Yogurt Pregnant Women, Undernourished + Yogurt Pregnant Women
C: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
D: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GR-1 | Arm Label: Milk; Type: OTHER; Interventions: Dietary Supplement: Pasteurized Whole Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Pasteurized Whole Milk; Assigned to Arm(s): Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GR-1; Assigned to Arm(s): Probiotic

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention Allergic Disease of Infant With Probiotics During Pregnancy and Neonate
Brief Summary: The purpose of this study is to determine whether childhood atopic disease decrease or not after allowing allergic mothers intake of probiotic (Lactobacillus GG) in second trimester, followed by infant intake for 6 months after birth.


Options:
A: Intervention Type: DRUG; Name: Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu); Assigned to Arm(s): N/A
B: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
C: Arm Label: LP GMNL-133 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 capsule | Arm Label: LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LF GM-090 capsule | Arm Label: LP GMNL-133+LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 +LF GM-090 capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 capsule; Assigned to Arm(s): LP GMNL-133 group | Intervention Type: BIOLOGICAL; Name: LF GM-090 capsule; Assigned to Arm(s): LF GM-090 group | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 +LF GM-090 capsule; Assigned to Arm(s): LP GMNL-133+LF GM-090 group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Infants drink formula added with LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Casein hydrolysate added with LGG | Arm Label: Infants drink casein hydrolysate without LGG; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Infants drink casein hydrolysate without LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Casein hydrolysate added with LGG; Assigned to Arm(s): Infants drink formula added with LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Infants drink casein hydrolysate without LGG; Assigned to Arm(s): Infants drink casein hydrolysate without LGG

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension
Brief Summary: This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12.

Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).


Options:
A: Arm Label: UT-15C (oral treprositnil); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) Sustained Release Tablets; Assigned to Arm(s): UT-15C (oral treprositnil) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selexipag | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selexipag; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Remodulin (treprostinil sodium); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension
Brief Summary: This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits occurred at 4 week intervals for 16 weeks; the key measure of efficacy was the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. One optional substudy was also a part of FREEDOM-C at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 16.

Patients who completed all assessments for 16-weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).


Options:
A: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) sustained release tablets; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: UT-15C (oral treprositnil); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Oral treprostinil (UT-15C) Sustained Release Tablets; Assigned to Arm(s): UT-15C (oral treprositnil) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Ventavis (Iloprost, BAYQ6256) | Intervention Type: DRUG; Name: Ventavis (Iloprost, BAYQ6256); Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Site Replication of an Inpatient Palliative Care Program
Brief Summary: Palliative care is believed to improve care of patients with life-limiting illnesses. This study evaluated the impact of a multi-center randomized trial of a palliative care team intervention on the quality and cost of care of hospitalized patients. Study subjects were randomized to intervention or usual care. At study end, patients receiving the palliative care intervention reported greater patient satisfaction with their care. Intervention patients also had significantly fewer ICU admissions and lower total costs for care 6 months past their hospitalization. Intervention patients completed more advance directives and had longer hospice stays.


Options:
A: Arm Label: Early entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early palliative care intervention | Arm Label: Later entry group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Later entry group | Intervention Type: BEHAVIORAL; Name: Later entry group; Assigned to Arm(s): Later entry group | Intervention Type: BEHAVIORAL; Name: Early palliative care intervention; Assigned to Arm(s): Early entry group
B: Intervention Type: BEHAVIORAL; Name: Multidisciplinary palliative care team met with patient; Assigned to Arm(s): N/A
C: Arm Label: early palliative care; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional palliative care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard oncologic care | Intervention Type: BEHAVIORAL; Name: Interventional palliative care; Assigned to Arm(s): early palliative care | Intervention Type: BEHAVIORAL; Name: Standard oncologic care; Assigned to Arm(s): Standard care
D: Arm Label: Early Palliative Care Referral; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Arm Label: Conventional Cancer Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Early Palliative Care Referral | Intervention Type: BEHAVIORAL; Name: Early Palliative Care Referral; Assigned to Arm(s): Conventional Cancer Care, Early Palliative Care Referral

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 16 Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy.
Brief Summary: A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.


Options:
A: Arm Label: Olanzapine or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amisulpride, Drug: Olanzapine and Amisulpride | Arm Label: Amisulpride or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Olanzapine and Amisulpride | Arm Label: Olanzapine and Amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Amisulpride | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine and Amisulpride | Intervention Type: DRUG; Name: Amisulpride; Assigned to Arm(s): Olanzapine and Amisulpride, Olanzapine or Placebo | Intervention Type: DRUG; Name: Olanzapine and Amisulpride; Assigned to Arm(s): Amisulpride or Placebo, Olanzapine or Placebo
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: pimozide; Type: EXPERIMENTAL; Interventions: Drug: Pimozide | Intervention Type: DRUG; Name: Pimozide; Assigned to Arm(s): pimozide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Quetiapine or Risperidone + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + Aripiprazole | Arm Label: Quetiapine or Risperidone + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + placebo | Intervention Type: DRUG; Name: Quetiapine or Risperidone + Aripiprazole; Assigned to Arm(s): Quetiapine or Risperidone + Aripiprazole | Intervention Type: DRUG; Name: Quetiapine or Risperidone + placebo; Assigned to Arm(s): Quetiapine or Risperidone + placebo
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects
Brief Summary: The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance


Options:
A: Arm Label: Bright light therapy; Type: EXPERIMENTAL; Interventions: Device: Bright light therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bright light therapy; Assigned to Arm(s): Bright light therapy
B: Arm Label: Ramelteon 8 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Ramelteon | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ramelteon; Assigned to Arm(s): Ramelteon 8 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group
D: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Benefits of Ambulatory Oxygen in Hypoxemic COPD Patients
Brief Summary: Chronic Obstructive Pulmonary Disease (COPD) affects over 14 million people in the United States. It is the fourth leading cause of death and the only leading cause of death for which mortality rates are rising. Medical science has developed few effective therapies for COPD. In patients with advanced COPD and chronic hypoxemia, long-term oxygen therapy (LTOT) has been shown to be uniquely beneficial. It is the only available non-surgical therapy demonstrated to prolong survival in these patients. This study will compare the clinical and physiologic benefits of two different oxygen therapy devices among hypoxemic individuals with COPD: a lightweight ambulatory oxygen device versus the standard portable E-cylinder device.


Options:
A: Arm Label: Treatment sequence I; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Arm Label: Treatment sequence II; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVA149, Drug: Placebo | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): Treatment sequence I, Treatment sequence II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment sequence I, Treatment sequence II
B: Arm Label: E-Cylinder; Type: ACTIVE_COMPARATOR; Interventions: Device: E-Cylinder | Arm Label: Lightweight Cylinder; Type: ACTIVE_COMPARATOR; Interventions: Device: Lightweight Cylinder | Intervention Type: DEVICE; Name: E-Cylinder; Assigned to Arm(s): E-Cylinder | Intervention Type: DEVICE; Name: Lightweight Cylinder; Assigned to Arm(s): Lightweight Cylinder
C: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management
D: Arm Label: Home-based pulmonary rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based pulmonary rehabilitation | Arm Label: Hospital-based pulmonary rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hospital-based pulmonary rehabilitation | Intervention Type: BEHAVIORAL; Name: Home-based pulmonary rehabilitation; Assigned to Arm(s): Home-based pulmonary rehabilitation | Intervention Type: BEHAVIORAL; Name: Hospital-based pulmonary rehabilitation; Assigned to Arm(s): Hospital-based pulmonary rehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations
Brief Summary: The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations
Brief Summary: The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
C: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Chronic Macrolide Administration on the Frequency and Severity of COPD Exacerbations
Brief Summary: The purpose of this study is to determine if long-term administration of a macrolide antibiotic will reduce worsening of symptoms among individuals with chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Moxifloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Moxifloxacin | Arm Label: Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Doxycycline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): N/A

Answer: B